| P50 | author | Ivan Delgado-Enciso | Q47225540 |
| | Augusto Rojas-Martinez | Q56974609 |
| | Rocio Ortiz-Lopez | Q56989572 |
| P2093 | author name string | H A Barrera-Saldaña | |
| | E B Butler | |
| | J P Flores-Gutiérrez | |
| | L K Aguilar | |
| | E Aguilar-Cordova | |
| | R Garza-Guajardo | |
| | S W Sukin | |
| | L Gomez-Guerra | |
| | J F González-Guerrero | |
| | A G Manzanera | |
| | G Elizondo Riojas | |
| | J Esteban-María | |
| P2860 | cites work | Cancer statistics, 2010 | Q27860525 |
| | In situ gene therapy for adenocarcinoma of the prostate: a phase I clinical trial. | Q33328885 |
| | Population based prostate cancer screening in north Mexico reveals a high prevalence of aggressive tumors in detected cases | Q33421572 |
| | Natural history of progression after PSA elevation following radical prostatectomy | Q33611613 |
| | Dose escalation for prostate cancer radiotherapy: predictors of long-term biochemical tumor control and distant metastases-free survival outcomes | Q33679365 |
| | TIA-1 cytotoxic granule-associated RNA binding protein improves the prognostic performance of CD8 in mismatch repair-proficient colorectal cancer | Q33778276 |
| | Phase IB study of gene-mediated cytotoxic immunotherapy adjuvant to up-front surgery and intensive timing radiation for malignant glioma | Q34208293 |
| | Gene therapy for brain tumors: regression of experimental gliomas by adenovirus-mediated gene transfer in vivo | Q35152561 |
| | Cytoreduction surgery reduces systemic myeloid suppressor cell populations and restores intratumoral immunotherapy effectiveness | Q36161355 |
| | Natural history of biochemical recurrence after radical prostatectomy: risk assessment for secondary therapy | Q36714200 |
| | Clinical practice. Localized prostate cancer | Q37045441 |
| | Cytotoxic immunotherapy strategies for cancer: mechanisms and clinical development | Q37861631 |
| | High-risk prostate cancer: combination of high-dose, high-precision radiotherapy and androgen deprivation therapy | Q38106832 |
| | Adjuvant radiotherapy for pathologically advanced prostate cancer: a randomized clinical trial | Q38402168 |
| | The combination of adenoviral HSV TK gene therapy and radiation is effective in athymic mouse glioblastoma xenografts without increasing toxic side effects. | Q40568783 |
| | Induction of potent antitumor natural killer cell activity by herpes simplex virus-thymidine kinase and ganciclovir therapy in an orthotopic mouse model of prostate cancer | Q41017590 |
| | Adenovirus-mediated herpes simplex virus thymidine kinase gene and ganciclovir therapy leads to systemic activity against spontaneous and induced metastasis in an orthotopic mouse model of prostate cancer | Q41133838 |
| | Prodrug-activated gene therapy: involvement of an immunological component in the "bystander effect". | Q41221700 |
| | Immune-dependent distant bystander effect after adenovirus-mediated suicide gene transfer in a rat model of liver colorectal metastasis | Q43550584 |
| | In vivo surgical resection plus adjuvant gene therapy in the treatment of mammary and prostate cancer | Q43586830 |
| | Enhanced therapeutic effect of HSV-tk+GCV gene therapy and ionizing radiation for prostate cancer | Q43586837 |
| | Temozolomide enhances herpes simplex virus thymidine kinase/ganciclovir therapy of malignant glioma. | Q43761368 |
| | Cancer gene therapy with HSV-tk/GCV system depends on T-cell-mediated immune responses and causes apoptotic death of tumor cells in vivo | Q43803202 |
| | Virus specific immune responses after human neoadjuvant adenovirus-mediated suicide gene therapy for prostate cancer. | Q45444616 |
| | Biological response determinants in HSV-tk + ganciclovir gene therapy for prostate cancer | Q45856165 |
| | Adenovirus-mediated gene therapy of experimental gliomas | Q45870226 |
| | Systemic gene therapy of murine melanoma using tissue specific expression of the HSVtk gene involves an immune component. | Q45871117 |
| | Prostate cancer, Version 3.2012: featured updates to the NCCN guidelines. | Q53362428 |
| | Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: long-term results of a randomised controlled trial (EORTC trial 22911) | Q63966469 |
| | Death in patients with recurrent prostate cancer after radical prostatectomy: prostate-specific antigen doubling time subgroups and their associated contributions to all-cause mortality | Q80242609 |
| P433 | issue | 11 | |
| P921 | main subject | immunotherapy | Q1427096 |
| | prostate cancer | Q181257 |
| P304 | page(s) | 642-649 | |
| P577 | publication date | 2013-09-20 | |
| P1433 | published in | Cancer Gene Therapy | Q15763088 |
| P1476 | title | Intraprostatic distribution and long-term follow-up after AdV-tk immunotherapy as neoadjuvant to surgery in patients with prostate cancer | |
| P478 | volume | 20 | |